Abstract
In this study, we estimate the severity of the COVID-19 outbreak in Pakistan prior to and after lockdown restrictions were eased. We also project the epidemic curve considering realistic quarantine, social distancing, and possible medication scenarios. We use a deterministic epidemic model that includes asymptomatic, quarantined, isolated, and medicated population compartments for our analysis. We calculate the basic reproduction number R0 for the pre and post lockdown periods, noting that during this time, no medication was available. The pre-lock down the value of R0 is estimated to be 1.07, and the post lockdown value is estimated to be 1.86. We use this analysis to project the epidemic curve for a variety of lockdown, social distancing, and medication scenarios. We note that if no substantial efforts are made to contain the epidemic, it will peak in mid of September, with the maximum projected active cases being close to 700,000. In a realistic, best-case scenario, we project that the epidemic peaks in early to mid-July with the maximum active cases being around 120000.We note that social distancing measures and medication, if available, will help flatten the curve, however without the reintroduction of further lockdown, it would be very difficult to bring R0 below 1. Our study strongly supports the recent WHO recommendation of reintroducing lockdowns to control the epidemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no funds were available during this project
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
https://github.com/CSSEGISandData/COVID-19
